Johnson & Johnson ($JNJ) is Expected to Lead Competitors with an Ad Spend Bump of 4.6% or More than $2 Billion
June 22, 2015
Johnson & Johnson’s Ethicon’s Gynecare mesh victims, Johnson & Johnson DePuy Synthes hip victims, and Johnson & Johnson Janssen Pharmaceutical Risperdal victims awaiting settlements from injury will be happy to know that Johnson & Johnson ($JNJ) is expected to lead competitors with an ad spend bump of 4.6% for total advertising spending reaching over $2 billion for 2016. FiercePharma Marketing